Form 10-Q Biohaven Pharmaceutical For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UBS Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
August 10, 2021 7:01 AM EDTUBS analyst Esther Rajavelu downgraded Biohaven Pharmaceutical Holding (NYSE: BHVN) from Buy to Neutral with a price target of $109.00 (from $108.00).
The analyst comments "We are moving to Neutral from Buy following a strong 1H21 stock performance for BHVN, primarily driven by Nurtec... More
